Stock offerings

Stock offerings

Thiogenesis Therapeutics Corp. Announces Private Placement of $1.5 Million to Fund Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS) Clinical Trial Expenses

Thiogenesis Therapeutics Corp. has announced a non-brokered private placement of $1.5 million to fund the company's Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS) clinical trial expenses, as well as the creation and purchase of additional TTI-0102 for future clinical trials. Key Takeaways: * Thiogenesis Therapeutics Corp. will undertake